Adverse effects of new biological therapies for non-small-cell bronchial cancer;Effets indésirables des nouvelles thérapeutiques biologiques du cancer bronchique non à petites cellules

Presse Medicale

Volumn 40, Issue 4 PART1, 2011, Pages 415-419

  Castel, Marion ^a   Pathak, Atul ^a   Despas, Fabien ^a   Mazières, Julien ^b  

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CALCIUM CHANNEL BLOCKING AGENT; CYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTERY THROMBOSIS; BIOLOGICAL THERAPY; DISEASE CONTROL; EPISTAXIS; GENERAL PRACTITIONER; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; SHORT SURVEY; SKIN CARE; SKIN TOXICITY; CANCER STAGING; COMPARATIVE STUDY; COOPERATION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; INTERDISCIPLINARY COMMUNICATION; LUNG TUMOR; MORTALITY; PATHOLOGY; PATIENT CARE; PROGNOSIS; REVIEW;

ANGIOGENESIS INHIBITORS; BIOLOGICAL PRODUCTS; CARCINOMA, NON-SMALL-CELL LUNG; COOPERATIVE BEHAVIOR; DISEASE-FREE SURVIVAL; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG NEOPLASMS; NEOPLASM STAGING; PATIENT CARE TEAM; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79958791438     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.02.004     Document Type: Short Survey

References (15)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
3. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Jia Y., Lacouture M.E., Su X., Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2009, 7:211-217.
6. Tan E.H., Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009, 43:1658-1666.
7. Deplanque G., Chavaillon J., Vergnenegre A., Falchero L., Fraboulet G., Gervais R., et al. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010, 28:15s. [abstract 9019].
8. Wacker B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P.J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
9. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
10. Soria JC, Mauguen A, Reck M, Sandler A, Nishio M, Johnson D, et al. Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ESMO 2010 Congress (Milan): p. 437.
11. Jubb M.A., Harris L. Biomarkers to predict clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-1183.
12. Eskens F., Verweij J. The clinical toxicity profile of VEGF and VEGFR targeting angiogenesis inhibitors, a review. Eur J Cancer 2006, 42:3127-3139.
13. Halimi J.M., Aziz M., Bobrie G., Bouche O., Deray G., des Guetz G., et al. Effets vasculaire et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique (SN, SFHTA, APNET, FFCD). Nephrol Ther 2008, 4:602-615.
14. Senellart H., Bennouna J. Bevacizumab and arterial hypertension or proteinuria: management. Rev Mal Respir 2008, 25:767-772.
15. Nalluri S.R., Chu D., Kereztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 2008, 300:2277-2278.